Kurume, Japan

Keiichi Mitsuyama


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Keiichi Mitsuyama: Innovator in Crohn's Disease Testing

Introduction

Keiichi Mitsuyama is a notable inventor based in Kurume, Japan. He has made significant contributions to the field of medical diagnostics, particularly in relation to Crohn's disease. His innovative work has led to the development of a specific epitope peptide that aids in the testing and diagnosis of this condition.

Latest Patents

Mitsuyama holds a patent for a "Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease." This patent describes an epitope peptide capable of binding specifically to an antibody characteristic of Crohn's disease, which is observed in affected patients. The invention includes a test method that allows for the convenient and rapid determination of whether a subject is affected by Crohn's disease using the peptide. The epitope peptide comprises amino acid sequences represented by any one of SEQ ID NOS: 1 to 3 or a salt thereof. This advancement is crucial for improving diagnostic accuracy and patient care.

Career Highlights

Throughout his career, Keiichi Mitsuyama has worked with prominent organizations, including Toagosei Company, Ltd. and Kurume University. His experience in these institutions has contributed to his expertise in medical research and innovation.

Collaborations

Mitsuyama has collaborated with notable colleagues such as Mikio Niwa and Katsuhiko Matsuo. These partnerships have likely enhanced his research and development efforts in the field of medical diagnostics.

Conclusion

Keiichi Mitsuyama's contributions to the diagnosis of Crohn's disease through his patented epitope peptide represent a significant advancement in medical technology. His work continues to impact the field positively, providing valuable tools for healthcare professionals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…